ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Funda Meric-Bernstam
Matched on ORCID iD 0000-0001-6816-6072; OpenAlex author ID A5076426660; NIH RePORTER profile ID 1949850. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 1
- Labs led
- 0
- Collaborators
- 34
2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 grant · 2023: 1 paper
Papers 3
- Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Tri… Co-author DOI 10.1007/s12029-023-00930-7↗
- High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Co-author DOI 10.1093/annonc/mdx004↗
- Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Co-author DOI 10.18632/oncotarget.19897↗
Grants 1
Closest collaborators
The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jack Roth · 1 shared grant, 2022 · strength 0.45
- Jason B. Fleming · 1 shared grant, 2022 · strength 0.45
- Scott Kopetz · 1 shared grant, 2022 · strength 0.45
- Robert A. Wolff · 2 shared papers, 2017–2023 · strength 0.22
- Paper Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immu… DOI 10.1007/s12029-023-00930-7↗
- Paper Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Cent… DOI 10.18632/oncotarget.19897↗
- Vivek Subbiah · 2 shared papers, 2017–2023 · strength 0.22
- Paper Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immu… DOI 10.1007/s12029-023-00930-7↗
- Paper Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Cent… DOI 10.18632/oncotarget.19897↗
- David S. Hong · 2 shared papers, 2017–2023 · strength 0.22
- Paper Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immu… DOI 10.1007/s12029-023-00930-7↗
- Paper Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Cent… DOI 10.18632/oncotarget.19897↗
- Aung Naing · 2 shared papers, 2017–2023 · strength 0.22
- Paper Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immu… DOI 10.1007/s12029-023-00930-7↗
- Paper Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Cent… DOI 10.18632/oncotarget.19897↗
- Jane Elizabeth Rogers · 1 shared paper, 2023 · strength 0.17
- Rishi Surana · 1 shared paper, 2023 · strength 0.17
- Jordi Ahnert Rodon · 1 shared paper, 2023 · strength 0.17
- Brandon George Smaglo · 1 shared paper, 2023 · strength 0.17
- Timothy Anthony Yap · 1 shared paper, 2023 · strength 0.17
- Shubham Pant · 1 shared paper, 2023 · strength 0.17
- Gauri Rajani Varadhachary · 2 shared papers, 2017 · strength 0.10
- Paper Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Cent… DOI 10.18632/oncotarget.19897↗
- Paper High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. DOI 10.1093/annonc/mdx004↗
- Milind M. Javle · 1 shared paper, 2017 · strength 0.05
- Sarina Anne Piha-Paul · 1 shared paper, 2017 · strength 0.05
- Jennifer Brooke Goldstein · 1 shared paper, 2017 · strength 0.05
- Chad Z. Tang · 1 shared paper, 2017 · strength 0.05
- Kenneth R. Hess · 1 shared paper, 2017 · strength 0.05
- Apostolia Maria Tsimberidou · 1 shared paper, 2017 · strength 0.05
- David R. Fogelman · 1 shared paper, 2017 · strength 0.05
- Siqing Fu · 1 shared paper, 2017 · strength 0.05
- Michael James Overman · 1 shared paper, 2017 · strength 0.05
- Ignacio Ivan Wistuba · 1 shared paper, 2017 · strength 0.05
- Matthew H. G. Katz · 1 shared paper, 2017 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.